2007 1.Niijima, K. ・Enta, K.・Hori, H.・Sashihara, S.・Mizoue, T.・Morimoto, Y.: The usefulness of sleep apnea syndrome screening using a portable pulse oximeter in the workplace J Occupat Health 49(1):1 - 8 2007. 1. 2.Yoshimura, R. ・Shinkai, K.・Ueda, N.・Nakamura, J.: Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients Pharmacopsychiatry 40(1):9 - 13 2007. 1. 3.Hori, H. ・Yoshimura, R.・Yamada, Y.・Sugita A・Mitoma, M.・Yoshishige, I.・Nakamura, J.: Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients Int Clin Psychopharmacol 22(1):21 - 27 2007. 1. 4.Inoue, Y. ・Terao, T.・Iwata, N.・Okamoto, K.・Kojima, H.・Okamoto, T.・Yoshimura, R.・Nakamura, J.: Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings form neuroendocrine challenge tests Psychopharmacology 190(2):213 - 219 2007. 2. 5.Naoe, Y. ・Shinkai, T.・Hori, H.・Fukunaka, Y.・Utsunomiya, K.・Sakata, S.・Matsumoto, C.・Shimizu, K.・Hwang, R.・Ohmori, O.・Nakamura, J.: No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations Neurosci Lett 415(2):108 - 112 2007. 3. 6.Shinkai, K. ・Toyohira, Y.・Yoshimura, R.・Tsutsui, M.・Ueno, S.・Nakamura, J.・Yanagihara, N.: Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran Naunyn Schmiedebergs Arch Pharmacol 375(1):65 - 72 2007. 3. 7.Yoshimura, R. ・Mitoma, M.・Sugita A・Hori, H.・Okamoto, T.・Umene, W・Ueda, N.・Nakamura, J.: Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31(5):1034 - 1037 2007. 6. 8.Yoshimura, R. ・Hori, H.・Sugita A・Ueda, N.・Kakihara, S.・Umene, W・Nakano, Y.・Shinkai, K.・Mitoma, M.・Ohta, M.・Shinkai, T.・Nakamura, J.: Treatment with risperidone for 4 weeks increased plasma 3 - methoxy - 4 - hydroxypnenylglycol(MHPG)levels, but did not alter plasma brain - derived neurotrophic factor (BDNF)levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31(5):1072 - 1077 2007. 6. 9.Shinkai, T. ・De Luca, V.・Hwang, R.・Müller, DJ.・Lanktree, M.・Zai, G.・Shaikh, S.・Wong, G.・Sicard, T.・Potapova, N.・Trakalo, J.・King, N.・Matsumoto, C.・Hori, H.・Wong, A.H.C.・Ohmori, O.・Macciardi, F.・Nakamura, J.・Kennedy, JL.: Association Analyses of the DAOA/G30 and D-Amino-Acid Oxidase Genes in Schizophrenia NeuroMolecular Medicine 9(2):169 - 178 2007. 7. 10.Sugita A ・Yoshimura, R.・Hori, H.・Ueda, N.・Nakamura, J.: Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa Psychiatry Clin Neurosci 61(4):452 - 2007. 8. 11.Miyamoto, K. ・Yoshimura, R.・Ueda, N.・Sugita A・Umene, W・Hori, H.・Mitoma, M.・Nakamura, J.: Effects of acute paroxetine treatment on the consumption of cigarette smokinf and caffeine in depressed patients Human Psychopharmacology 22:483 - 490 2007. 8. 12.Yamanouchi, Y. ・Ikeda, M.・Yoshimura, R.・Hashimoto, S.・Nakamura, J.・Ozaki, N.・Iwata, N.: Gene variants of dopamine receptors as predictors of response to risperidone treatment in first-episode schizophrenia patients Int Clin Psychopharmacol 22(5):A3 - 2007. 9. 13.Shinkai, T. ・Hori, H.・Matsumoto, C.・Utsunomiya, K.・Sakata, S.・Naoe, Y.・Fukunaka, Y.・Shimizu, K.・Ohmori, O.・Nakamura, J.: MDR1 genetic polymorphism and tardive dyskinesia Int Clin Psychopharmacol 22(5):A3 - A4 2007. 9. 14.Yoshimura, R. ・Sugita A・Hori, H.・Mitoma, M.・Nakamura, J.: Effects of SSRI or SNRI on serum brain-derived neurotrophic factor levels in depressed patients Int Clin Psychopharmacol 22(5):A12 - A13 2007. 9. 15.Okamoto, T. ・Yoshimura, R.・Nakamura, J.: BDNF and catecholamine metabolites levels in psychotic depression recovered by the modified ECT: a case report Int Clin Psychopharmacol 22(5):A15 - 2007. 9. 16.Yoshimura, R. ・Kakihara, S.・Ueda, N.・Shinkai, K.・Nakamura, J.: Effects of nicotine and caffeine on response to risperidone treatment in schizophrenia Int Clin Psychopharmacol 22(5):A22 - 2007. 9. 17.Nakano, Y. ・Yoshimura, R.・Sugita A・Hori, H.・Nakano, H.・Nakata, S.・Tsutsui, M.・Yanagihara, N.・Nakamura, J.: Plasma NOx levels in schizophrenic patients:preliminary study Int Clin Psychopharmacol 22(5):A22 - A23 2007. 9. 18.Tsuji, T. ・Yoshimura, R.・Nakamura, J.: Serum brain-derived neurotrophic factor levels are increased in psychotic depressed patients responding to lithium addition to paroxetine treatment Int Clin Psychopharmacol 22(5):A23 - 2007. 9. 19.Sugita A ・Yoshimura, R.・Ueda, N.・Nakamura, J.: Therapeutic drug montitoring of plasma fluvoxamine level is useful in the treatment of bulimia nervosa Int Clin Psychopharmacol 22(5):A23 - A24 2007. 9. 20.Yoshimura, R. ・Miyamoto, K.・Ueda, N.・Nakamura, J.: Effects of nicotine and caffeine on response to paroxetine treatment in depressed patients Int Clin Psychopharmacol 22(5):A25 - 2007. 9. 21.Sugita A ・Yoshimura, R.・Hori, H.・Nakano, Y.・Nakano, H.・Nakata, S.・Tsutsui, M.・Yanagihara, N.・Nakamura, J.: The influence of SSRI and SNRI on blood nitric oxide concentration Int Clin Psychopharmacol 22(5):A25 - A26 2007. 9. 22.Hori, H. ・Yoshimura, R.・Shinohara, Y.・Iwamoto, M.・Takahashi, K.・Nakamura, J.: Plasma valproic acid levels in acute manic phase and the following maintenance phase in bipolar patients Int Clin Psychopharmacol 22(5):A26 - 2007. 9. 23.Hwang, R. ・Shinkai, T.・De, Luca V.・Ni, X.・Potokin, SG.・Liebirman, JA.・Meltzer, HY.・Kennedy, JL.: Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 21(7):718 - 727 2007. 9. 24.Song, YH. ・Terao, T.・Nakamura, J.: Tyape A behaviour pattern is associated with cynicism and low self - acceptance in medical students Stress and Health 23:323 - 329 2007. 9. 25.Umene, W ・Yoshimura, R.・Hori, H.・Nakano, H.・Sugita A・Shimono, M.・Takano, K.・Shiota, N.・Tomoda, Y.・Korogi, Y.・Nakamura, J.: Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea World J Biol Psychiatry 26:1 - 4 2007. 10. 26.Yoshimura, R. ・Kobayashi, K.・Naoe, Y.・Okamoto, T.・Nakamura, J.: Late - onset catatonia responding to treatment with aripiprazole International Psychogeriatrics 19:1:203 - 2007. 10. 27.Yoshimura, R. ・Tsuji, T.・Ueda, N.・Nakamura, J.: Increase of plasma brain-derived neurotrophic factor levels in two psychotic depressed patients responding to lithium addition to paroxetine treatment Neuropsychiatric Disease Treatment 3(5):683 - 686 2007. 11. 28.Fukunaka, Y. ・Shinkai, T.・Hwang, R.・Hori, H.・Utsunomiya, K.・Sakata, S.・Naoe, Y.・Shimizu, K.・Matsumoto, C.・Ohmori, O.・Nakamura, J.: The Orexin 1 Receptor (HCRTR1) Gene as a Susceptibility Gene Contributing to Polydipsia - Hyponatremia in Schizophrenia. Neuromolecular Med 9(4):292 - 297 2007. 12.

Source: http://www.uoeh-u.ac.jp/kouza/seisin/pdf/2007Publication.pdf

Microsoft word - jnmt42424 approved questions.doc

CONTINUING EDUCATION TEST: Cardiac CT: Indications and Limitations 1. At this time, why is CCT not recommended as a routine screening test for CAD? A. Too much overlapping of adjacent structures can cause false-positive and B. There are not enough data on the increased risks of cancer from this procedure. C. At this time, it does not provide a 3-dimensional view of the heart, which can D. It


M E R I D I A N P S Y C H O L O G I C A L A S S O C I A T E S 4401 North Central Avenue Indianapolis IN 46205 (317) 923-2333 FAX (317) 923-2333 [email protected] Dennis Mac Greene, Ph.D., HSPP Indiana License #: 20041237 National Register of Health Service Providers in Psychology #44394 Mailing Address: 1992 Ph.D. Clinical Psychology, Rutgers University, Brunswick, NJ 1989-

Copyright ©2010-2018 Medical Science